Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-
labeled PET agents has become increasingly important in recent years. Imaging of …

The aim of this guideline is to provide standards for the recommendation, performance,
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained
high attention as a promising new radiotracer in patients with prostate cancer (PC). Several …

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

As medical imaging has grown progressively more complicated and subspecialized in
recent decades, several standardized reporting systems have been proposed for a variety of …

Purpose 68 Ga-PSMA-11 is a novel PET tracer suggested to be used for imaging of
advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of 68 …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …